newsfilter
← Latest News
GlobeNewswire·

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patientsIn the 120 mg